Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
European Journal of Clinical Pharmacology|December 21, 2018
Practical risk management in early phase clinical trialsSimon Coates, Jörg Täubel, Ulrike LorchTherapeutic Innovation & Regulatory Science|February 3, 2020
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development ProgramsSimon Coates, Oliver Pohl, Jean-Pierre Gotteland, et al.British Journal of Clinical Pharmacology|March 21, 2019
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasoneOliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.British Journal of Clinical Pharmacology|May 1, 2018
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal womenOliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.Frontiers in Pharmacology|April 2, 2020
Time- and Race-Specific Haematological Reference Intervals for Healthy Volunteer Trials: A Retrospective Analysis of Pooled Data From Multiple Phase I TrialsSimon Coates, Duolao Wang, Tomasz Pierscionek, et al.Clinical Pharmacology in Drug Development|March 1, 2018
Confirmation of the Cardiac Safety of PGF<sub>2α</sub> Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG AssessmentsJörg Täubel, Ulrike Lorch, Simon Coates, et al.British Journal of Clinical Pharmacology|January 12, 2020
First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotectionM Farouk Chughlay, Emilie Rossignol, Cristina Donini, et al.British Journal of Clinical Pharmacology|June 2, 2021
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteersJӧrg Täubel, Ulrike Lorch, Georg Ferber, et al.Pageof 1